William Blair Forecasts uniQure’s Q1 Earnings (NASDAQ:QURE)

uniQure (NASDAQ:QURE) – William Blair dropped their Q1 2025 EPS estimates for shares of uniQure in a report released on Thursday, February 27th. William Blair analyst S. Corwin now forecasts that the biotechnology company will earn ($1.48) per share for the quarter, down from their previous forecast of ($0.73). The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure’s Q2 2025 earnings at ($1.48) EPS, Q3 2025 earnings at ($1.37) EPS, Q4 2025 earnings at ($1.37) EPS, FY2025 earnings at ($5.69) EPS and FY2026 earnings at ($5.28) EPS.

A number of other research analysts also recently commented on the stock. Stifel Nicolaus increased their price target on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 16th. Cantor Fitzgerald increased their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. Wells Fargo & Company lowered their price target on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Leerink Partners increased their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $38.89.

uniQure Stock Up 3.9 %

Shares of NASDAQ:QURE opened at $11.33 on Monday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a 50-day moving average price of $14.80 and a 200 day moving average price of $9.89. The company has a market cap of $552.26 million, a price-to-earnings ratio of -2.28 and a beta of 0.38.

Hedge Funds Weigh In On uniQure

Institutional investors have recently modified their holdings of the stock. Voloridge Investment Management LLC purchased a new position in uniQure during the fourth quarter valued at approximately $3,129,000. Woodline Partners LP purchased a new position in uniQure during the fourth quarter valued at approximately $2,484,000. Two Sigma Advisers LP increased its holdings in uniQure by 1.4% during the fourth quarter. Two Sigma Advisers LP now owns 756,900 shares of the biotechnology company’s stock valued at $13,367,000 after buying an additional 10,400 shares during the period. Two Sigma Investments LP increased its holdings in uniQure by 9.2% during the fourth quarter. Two Sigma Investments LP now owns 878,884 shares of the biotechnology company’s stock valued at $15,521,000 after buying an additional 73,988 shares during the period. Finally, Stempoint Capital LP purchased a new position in uniQure during the fourth quarter valued at approximately $1,589,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 26,727 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $285,978.90. Following the transaction, the chief executive officer now directly owns 571,188 shares of the company’s stock, valued at approximately $6,111,711.60. This trade represents a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the transaction, the chief financial officer now directly owns 155,168 shares in the company, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 55,915 shares of company stock valued at $588,112 in the last ninety days. 4.74% of the stock is owned by company insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.